AU2007266840B2 - Pyrrolo[1,2-A]pyrazin-1(2H)-one and pyrrolo[1,2-D][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP) - Google Patents

Pyrrolo[1,2-A]pyrazin-1(2H)-one and pyrrolo[1,2-D][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP) Download PDF

Info

Publication number
AU2007266840B2
AU2007266840B2 AU2007266840A AU2007266840A AU2007266840B2 AU 2007266840 B2 AU2007266840 B2 AU 2007266840B2 AU 2007266840 A AU2007266840 A AU 2007266840A AU 2007266840 A AU2007266840 A AU 2007266840A AU 2007266840 B2 AU2007266840 B2 AU 2007266840B2
Authority
AU
Australia
Prior art keywords
pyrazin
oxo
methyl
compound
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007266840A
Other languages
English (en)
Other versions
AU2007266840A1 (en
Inventor
Philip Jones
Olaf Kinzel
Laura Llauger Bufi
Ester Muraglia
Giovanna Pescatore
Caterina Torrisi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
St Di Ricerche Di Biologia Molecolare P Angeletti SpA
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0610670A external-priority patent/GB0610670D0/en
Priority claimed from GB0707359A external-priority patent/GB0707359D0/en
Application filed by St Di Ricerche Di Biologia Molecolare P Angeletti SpA, Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical St Di Ricerche Di Biologia Molecolare P Angeletti SpA
Publication of AU2007266840A1 publication Critical patent/AU2007266840A1/en
Application granted granted Critical
Publication of AU2007266840B2 publication Critical patent/AU2007266840B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2007266840A 2006-05-31 2007-05-29 Pyrrolo[1,2-A]pyrazin-1(2H)-one and pyrrolo[1,2-D][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP) Ceased AU2007266840B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0610670A GB0610670D0 (en) 2006-05-31 2006-05-31 Therapeutic compounds
GB0610670.2 2006-05-31
GB0707359.6 2007-04-17
GB0707359A GB0707359D0 (en) 2007-04-17 2007-04-17 Therapeutic compounds
PCT/GB2007/050300 WO2007138355A1 (en) 2006-05-31 2007-05-29 Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp)

Publications (2)

Publication Number Publication Date
AU2007266840A1 AU2007266840A1 (en) 2007-12-06
AU2007266840B2 true AU2007266840B2 (en) 2012-09-20

Family

ID=38377212

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007266840A Ceased AU2007266840B2 (en) 2006-05-31 2007-05-29 Pyrrolo[1,2-A]pyrazin-1(2H)-one and pyrrolo[1,2-D][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP)

Country Status (6)

Country Link
US (1) US7834015B2 (enExample)
EP (1) EP2032140A1 (enExample)
JP (1) JP5271897B2 (enExample)
AU (1) AU2007266840B2 (enExample)
CA (1) CA2652167A1 (enExample)
WO (1) WO2007138355A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
MX2009007053A (es) * 2006-12-28 2009-07-09 Abbott Lab Inhibidores de poli (adp-ribosa) polimerasa.
AR070221A1 (es) * 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0907515D0 (en) * 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
MX2012012059A (es) * 2010-04-16 2013-03-21 Abbvie Inc Inhibidores de pirrolopirazinona de cinasas.
EP2646428B1 (en) * 2010-12-02 2016-06-01 Shanghai De Novo Pharmatech Co Ltd. Heterocyclic derivatives, preparation processes and medical uses thereof
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
HRP20160908T1 (hr) * 2012-03-28 2016-09-23 Merck Patent Gmbh Biciklički derivati pirazinona
CA2870062A1 (en) * 2012-06-20 2013-12-27 F.Hoffmann-La Roche Ag Pyrrolopyrazone inhibitors of tankyrase
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
KR102073797B1 (ko) * 2014-07-07 2020-02-05 지앙수 헨그루이 메디슨 컴퍼니 리미티드 단백질 키나제 저해제로서의 아미노피리다지논 화합물
US9994570B2 (en) 2014-11-26 2018-06-12 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists
CN106749261A (zh) * 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
CN106939002B (zh) * 2016-01-05 2019-09-24 江苏恒瑞医药股份有限公司 一种btk激酶抑制剂的结晶形式及其制备方法
ES2875384T3 (es) 2016-01-05 2021-11-10 Jiangsu Hengrui Medicine Co Forma cristalina del inhibidor de la quinasa BTK y método de preparación del mismo
CN105646497B (zh) * 2016-02-01 2019-06-04 南京格亚医药科技有限公司 吡咯并三嗪酮衍生物
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
EP4065099A4 (en) 2019-11-25 2023-11-29 The Research Foundation for The State University of New York COMBINATION THERAPY USING FABP5 INHIBITORS WITH TAXANS FOR THE TREATMENT OF CANCER
WO2021214502A1 (en) 2020-04-21 2021-10-28 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
KR102913343B1 (ko) 2020-04-21 2026-01-15 아이디언스 주식회사 프탈라지논 화합물의 결정형
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
WO2024046420A1 (zh) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 稠合二环类化合物、其制备方法及其在医药上的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
DE69521002T3 (de) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
HU228960B1 (hu) 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
WO2002090334A1 (en) 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
KR100663147B1 (ko) * 2002-02-19 2007-02-28 오노 야꾸힝 고교 가부시키가이샤 축합 피리다진 유도체 화합물 및 이를 유효 성분으로서함유하는 약제
DE60335359D1 (de) * 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
PL1633724T3 (pl) * 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CA2557547A1 (en) 2004-02-26 2005-09-09 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
KR20070057859A (ko) 2004-08-26 2007-06-07 쿠도스 파마슈티칼스 리미티드 4-헤테로아릴메틸 치환된 프탈라지논 유도체
GB0615809D0 (en) 2006-08-09 2006-09-20 Istituto Di Ricerche D Biolog Therapeutic compounds
WO2008072779A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. キノキサリン誘導体
MX2009007053A (es) * 2006-12-28 2009-07-09 Abbott Lab Inhibidores de poli (adp-ribosa) polimerasa.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PEUKERT, S. ET AL. Expert Opin. Ther. Patents (2004) 14(11): 1531-1551 *

Also Published As

Publication number Publication date
EP2032140A1 (en) 2009-03-11
WO2007138355A1 (en) 2007-12-06
AU2007266840A1 (en) 2007-12-06
US20090209523A1 (en) 2009-08-20
US7834015B2 (en) 2010-11-16
JP5271897B2 (ja) 2013-08-21
CA2652167A1 (en) 2007-12-06
JP2009538897A (ja) 2009-11-12

Similar Documents

Publication Publication Date Title
US7834015B2 (en) Pyrrolo[1,2-a] pyrazin-1(2H)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)
AU2007266836B2 (en) Pyridinone and pyridazinone derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)
AU2007232297B2 (en) Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors
AU2009224004A1 (en) Tricyclic derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)
AU2007283212A1 (en) 4-oxo-4,5-dihydropyrrolo[1,2-A] quinoxaline derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP)
CA3199333A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
US20100173895A1 (en) Imidazolopyrimidines and imidazolotriazine derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
RU2472782C2 (ru) Производные пиридинона и пиридазинона в качестве ингибиторов поли(adp-рибоза) полимеразы (parp)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired